TXG
10x Genomics, Inc. · Healthcare · Medical - Healthcare Information Services
Momentum inputs (comparable managers):
holder breadth -9.5% ·
share flow -0.5% ·
net new positions -15.8%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 153.99K | $11.76M | n/a | n/a |
| Q2 2026 | 113 | +6 | 98.93M | $3.79B | +15 | −8 |
| Q1 2026 | 109 | +3 | 94.02M | $1.99B | +12 | −10 |
| Q4 2025 | 107 | +3 | 97.86M | $1.59B | +4 | n/a |
| Q3 2025 | 19 | -2 | 71.88M | $839.83M | n/a | −3 |
| Q2 2025 | 19 | +1 | 64.66M | $748.72M | +2 | −1 |
| Q1 2025 | 15 | 0 | 30.56M | $266.82M | +1 | −1 |
| Q4 2024 | 15 | +1 | 24.83M | $356.61M | +3 | −2 |
| Q3 2024 | 13 | 0 | 22.71M | $512.82M | +1 | −1 |
| Q2 2024 | 13 | n/a | 21.07M | $409.76M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 13.27M | +6.7% | $155.18M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | ARK Investment Management ✦ | 11.89M | -14.4% | $138.96M | 0.8% | ▼ Trim | 6 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 9.46M | +0.3% | $110.59M | 0.0% | ▲ Add | 2 | SEC ↗ ×17 |
| 4 | Fidelity (FMR) ✦ | 8.46M | -6.0% | $98.87M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 5 | Millennium Management ✦ | 5.44M | +88.6% | $63.57M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 6 | Wellington Management ✦ | 4.29M | +126.6% | $50.10M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 7 | Morgan Stanley ✦ | 2.82M | n/a | $32.93M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 8 | Geode Capital Management ✦ (passive) | 2.71M | +2.3% | $31.70M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | AQR Capital Management ✦ | 2.73M | -34.1% | $31.47M | 0.0% | ▼ Trim | 6 | SEC ↗ ×6 |
| 10 | Goldman Sachs Group ✦ | 2.68M | n/a | $31.27M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 11 | State Street Global Advisors ✦ (passive) | 2.52M | +1.1% | $29.46M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | JPMorgan Chase ✦ | 2.15M | n/a | $25.11M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 13 | Capital World Investors ✦ | 1.45M | 0.0% | $16.98M | 0.0% | Held | 6 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 1.04M | -29.0% | $12.22M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 591.39K | -42.4% | $6.91M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 162.91K | -78.2% | $1.90M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 17 | T. Rowe Price ✦ | 152.83K | -43.6% | $1.79M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 18 | Marshall Wace ✦ | 51.00K | -87.2% | $596,178 | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 19 | Gotham Asset Management ✦ | 18.93K | -75.3% | $221,315 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Citadel Advisors | $2.27M | was 0.0% |
| Arrowstreet Capital | $1.43M | was 0.0% |
| Norges Bank | $841,565 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 328 holders, 124.40M shares, $2.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.00K sh · $78,228
Director · 1.22K sh · $100,542
Director · 2.27K sh · $185,391
Director · 1.32K sh · $107,082
Director · 614 sh · $48,820
Director · 292 sh · $22,833
Officer, Director · 2.80K sh · $230,622
Officer, Director · 9.90K sh · $810,071
Officer, Director · 9.30K sh · $752,401
Officer, Director · 2.00K sh · $159,239
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology